Large numbersofspecimens(5000-18 000) were screened for amphetamines, barbiturates, cocaine, manjuana, opiates, and phencyclidine by RIA (Roche), EmitII (Syva), and a new immunoassay,CEDIA (cloned enzyme donorimmunoassay, Microgenics). Allimmunoassaysperformed equivalently for cocaine, opiates, and phencydidine. All immunoassaysdetected the same amphetamine/methamphetamine-positive specimens, but all also detected numerousspecimenscontaining cross-reacting sympathomimetic amines.CEDL detected 100%, Emit1193%, and RIA 82% ofthebarbituratepositive specimens. EmitIIand CEDIA detected 86-88% of the specimensfound by RIA to be manjuana positive. A subset of specimens was additionally screened by OnUne (Roche) and TDx (Abbott) for amphetamines, cocaine, and marijuana. OnLine arid TDx also detected all of the amphetamine-positive specimens and numerous specimens containing cross-reacting sympathomimetic amines. opiates, and phencycidine, using our routine RJA tests, Emit II, and CEDIA. All specimens that gave positive results by these assays 
and precise to detect the majority of positive specimens and be reliable to serve as an effective deterrent of drug abuse.
We previously evaluated the most commonly used screening tests, including the most recent enzyme im- opiates, and phencycidine, using our routine RJA tests, Emit II, and CEDIA. All specimens that gave positive results by these assays 
Materials and Methods

Immunoassay Screen Procedure
Batches of 200 urine specimens submitted to our laboratory from Air Force units in this country and around the world were tested by routine RIA procedures in accordance with the DOD drug-testing program. Each batch was analyzed for marijuana, cocaine, and a third drug-either amphetamines, barbiturates, 
Evaluation Studies
Calibration.
Rate of absorbance change data for Emit II and CEDIA for the negative, cutoff, and high calibrators were collected over 20 days. Mean, SD, and CV were calculated and calibration curves were drawn from the averaged values.
The CEDLA kits are designed to be used with either four or five calibrators; full calibration curves can be constructed, allowing semiquantitative results to be reported. We chose to use only the negative, cutoff value, and high calibrators to parallel the three calibrators used by the Emit II assays, which is the approach to immunoassay calibration used by most forensic urine drug testing laboratories.
Precision. Day-to-day (between-run) precision was determined for calibrators and controls assayed over 20 days. Emit II and CEDIA kit controls and in-house controls below and above the cutoff values for each drug were tested. Within-run precision was determined for 20 replicates of calibrators and controls assayed in a single run.
Method In all, 13 600 specimens were tested for amphetamines, 5000 for barbiturates, 15 600 for cocaine, 18 800 for marijuana, 5400 for opiates, and 8800 for phencycidine.
Most specimens screening positive for amphetamines, cocaine, or marijuana were additionally tested by TDx and OnLine (aliquots for some confirmed positive specimens were not available for forensic reasons).
Results
Assay Performance
The Emit methodology is well established, widely used, and will not be described here. Emit II, the latest formulation of this methodology, has previously been evaluated by us (1-3) . The Emit II operational characteristics offer advantages over Emit 700 and yield performance comparable with RJA, OnLine, and TDx assays.
The CEDJA methodology has been available for several years; it was described in 1986 as a new approach to homogeneous immunoassay (4, 5 
Precision
No calibrator
CVs for either assay exceeded 6.0%, very creditable performance.
In general, the Emit II assays exhibited slightly better precision than the CEDIA tests; see, e.g., the marijuana results. However, the CEDIA cocaine assay was remarkably consistent at all three calibrator concentrations, the CVs of 2.2-2.3% reflecting a bit better performance than the Emit II cocaine assay. For controls at 0.5 and 1.5 times the cutoff values, all CVs were <5.0%; Emit II again generally gave slightly better precision than CEDIA, except for the cocaine assay. For all practical purposes, the larger separation between calibrator concentrations achieved by CEDJA probably offsets any edge in precision enjoyed by Emit II.
The within-run precision data (not shown) were also impressive. The largest CV for any calibrator or control for either assay was <3.8%, and the majority of CVs for both assays were <2.5%. Table 2 lists the method comparison data for RIA, Emit II, CEDJA, and GC-MS. The three immunoassays were all comparable in terms of detection rates for amphetamines, every assay detecting all of the GC-MS confirmed positives. Additional specimens were screened by RIA and CEDIA but not by Emit II; RIA and CEDIA detected all confirmed amphetamine positives in this additional group of specimens.
Method Comparison
The positive detection rates given in Table 2 
232
18800
The performance of all immunoassays was identical 16 5400 for the opiates and phencyclidine, but the number of 4 8800 confirmed positives was admittedly low for both of these drugs. Only four phencycidine positives were found, probably external double-blind quality-control samples rather than specimens from actual phencyclidine users. Table 3 lists the method comparison data for five different immunoassays for amphetamines, cocaine, and marijuana. These specimens represent a subset of the screen positives from Table 2 that were also tested by OnLine and TDx. We emphasize that not all of the specimens listed in Table 2 that all of the immunoassays can be expected to detect amphetamineand methamphetamine-positive specimens equally well.
All of the immunoassays could also detect large numbers of unconfirinable specimens as well. Table 2 .
RIA
Again, about
10% of the confirmed positives were not detected by these two tests; OnLine and TDx detected 89% and 87%, respectively.
The detection rates for confirmed positives were within 3% of each other for all four nonisotopic immunoassays.
The majority of specimens not detected were low positives (CC-MS values 30 pgfL) and typically showed definite immunoassay reactivity, but at values below the screen cutoff response. We conclude that the performance of all of the nonisotopic tests is essentially equivalent.
Discussion
The results of the method comparison studies are consistent with those observed and reported by us previously, except for the inclusion of amphetamine data (1-3). Amphetamine assays are widely recognized as problematical because of the large number of falsepositive screen results they produce. The many sympathomimetic amine drugs found in over-the-counter (nonprescription) medications are the usual cause. These medications are regularly ingested in sufficient quantities to yield specimens with high enough concentrations of sympathomimetic amines to cross-react with the screen assays. Making antibodies that will bind only amphetamine and methamphetainine is probably an unachievable goal, given the large number of licit and unrestricted amphetamines that are so close in molecular structure to the controlled substances. It is actually beneficial to have amphetamine screen assays that are not overly specific because they can detect abused "designer" drugs such as methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA).
All of the immunoassays detect the GC-MS confirmable amphetamine positives. They also all detect numerous unconfirmable screen positives, on which unnecessary time, effort, and money are wasted.
CEDJA detects fewer false screen positives than Emit II, perhaps due to CEDIA's analytical sensitivity advantage or other factors, such as antibody specificity. However, our Emit II data must be interpreted cautiously because of our modification for a 500 j.tgfL cutoff instead the 1000 pg/L cutoff for which it is intended. The amphetamine calibration curve shows that the separation between the negative calibrator and a 1000 tgfL calibrator is considerably greater than for a 500 g/L calibrator. Moreover, it is reasonable to expect that most of these false screen positives would be eliminated by the use of an oxidizing agent with the Emit II, CEDIA, and OnLine assays to destroy the cross-reacting phenethylamines, as was demonstrated here by the RIA and TDx tests. Syva already offers an EMIT amphetamine confirmation kit to eliminate false screen positives on rescreen, but we have no experience with it.
Occasionally, we encounter specimens that are still positive on rescreen after sodium periodate treatment but that are not confirmed by GC-MS. Most clearly do not contain either of the controlled amphetamines but do exhibit large GC-MS peaks consistent with crossreacting sympathomimetic amines. In selected specimens from this study that were negative by RIA rescreen but strongly positive by TDx or one or more of the other iminunoassays, analysis by GC-MS showed, as expected, the presence of large concentrations of crossreacting sympathomimetic amines in all. Typical interferents were ephedrine and pseudoephedrine.
